GlassScriptPhysician profile
Shawn J Schmieder
NPI 1609225176
$10,527.81
in general payments reported to CMS, 2019-2025
37 companies · $1,573 in 2025
The $1,573 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,587 · 2020: $569 · 2021: $975 · 2022: $1,638 · 2023: $1,687 · 2024: $2,499 · 2025: $1,573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,645 · Education: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,644.62 |
| Education | $114.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,149.73 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Genzyme Corporation | $1,112.07 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $934.80 | 2019-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $869.60 | 2021-2025 | Adbry |
| Janssen Biotech, INC. | $803.30 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $684.01 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $547.66 | 2019-2024 | Ilumya, Winlevi, Absorica Ld |
| Pfizer INC. | $456.20 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $425.95 | 2019-2025 | |
| Galderma Laboratories, L.P. | $353.41 | 2019-2025 | Aklief, Nemluvio |
| Janssen Scientific Affairs, LLC | $314.12 | 2019-2020 | |
| Amgen INC. | $230.92 | 2021-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $181.17 | 2023-2025 | Zoryve |
| Organogenesis INC. | $170.52 | 2023-2025 | Puraply, Affinity |
| Kerecis Limited | $141.00 | 2023-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Surgiclose |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $137.10 | 2023-2024 | Vtama |
| Ucb, INC. | $126.85 | 2021-2025 | Bimzelx |
| Incyte Corporation | $123.78 | 2021-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $123.68 | 2022-2024 | Sotyktu |
| Celgene Corporation | $81.06 | 2019 | |
| Almirall LLC | $75.37 | 2020-2025 | Klisyri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.41 | 2023-2024 | Spevigo |
| Mayne Pharma Commercial LLC | $64.75 | 2021-2023 | |
| Sandoz INC. | $59.58 | 2023-2024 | Hyrimoz |
| Verrica Pharmaceuticals INC. | $37.93 | 2023 | Ycanth |
| Kyowa Kirin, INC. | $35.81 | 2023-2025 | Poteligeo |
| Organon LLC | $35.41 | 2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $31.75 | 2019-2025 | Cabtreo |
| Journey Medical Corporation | $22.16 | 2022 | |
| Lnhc, INC | $22.16 | 2025 | Zelsuvmi |
| Sebela Pharmaceuticals INC. | $18.59 | 2019 | |
| Dermira, INC. | $17.65 | 2019 | |
| Biofrontera INC. | $14.81 | 2022 | |
| Genentech USA, INC. | $14.73 | 2024 | Erivedge |
| Helsinn Therapeutics (U.S.), INC. | $13.93 | 2021 | |
| Promius Pharma LLC | $12.13 | 2019 | |
| Vyne Pharmaceuticals INC. | $11.71 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shawn Schmieder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.